13 hours Replimune Stock Rallies on BLA Filing for Melanoma Combo DrugZacks
REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.
Bristol · Bristol-Myers Squibb (BMY)
X